EUVIMEDEUVIMED entdecken
Open Access

Cancer-control outcomes with [ 177 Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patients

Mike Wenzel, Carolin Siech, Cristina Cano Garcia, Clara Humke, Daniel Groener, Maximilian Kriegmair, Markus Graefen, Tobias Maurer, Georg Salomon, Severine Banek, Felix K H Chun, Philipp Mandel

Theranostics · 27.01.2025 · 15 (7) · 2672-2679

DOI: 10.7150/thno.108963 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, erschienen am 27.01.2025. Verfasst von Mike Wenzel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Radiopharmaceuticals, Radioisotopes. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale: [177Lu]Lutetium prostate-specific membrane antigen radioligand therapy ([177Lu]Lu-PSMA) is EMA-approved for certain indications in metastatic castration resistant prostate cancer (mCRPC). However, cancer-control outcomes in specific and trial-underrepresented subgroups are scant.

Methods

We relied on the FRAMCAP database to elaborate progression-free (PFS) and overall (OS) survival in elderly (≥75 yrs), frail (ECOG status ≥1) mCRPC patients or those with cardiovascular disease (CVD) treated with [177Lu]Lu-PSMA.

Results

Of 312 [177Lu]Lu-PSMA mCRPC patients, 76% were ≤75 vs. 24% >75 years. Patients >75 years received [177Lu]Lu-PSMA more frequently within the first three mCRPC lines (85% vs. 62%) and harbored more frequently ECOG status ≥2 (13% vs. 4.3%, both p 75 years was observed (hazard ratios [HR] 0.97 & 0.85, both p≥0.4) with median PFS of 12.7 vs. 11.7 and OS of 15.1 vs. 19.8 months. In ECOG-stratified analyses, no PFS difference was observed, with significantly better OS for ECOG 0 vs. ≥1 (HR 1.69, p < 0.01), but not after further multivariable adjustment. In CVD-stratified analyses, PFS failed to provide significant differences between CVD vs. no CVD (HR: 1.44, p = 0.051). However, in OS analyses, significant worse OS for CVD mCRPC [177Lu]Lu-PSMA patients was observed (HR: 1.93, p < 0.01). After multivariable adjustment, CVD was an independent predictor for worse PFS and OS (both p < 0.01).

Conclusions

Real-world evidence suggests equally effective cancer-control outcomes in elderly and frail mCRPC patients treated with [177Lu]Lu-PSMA. However, patients with CVD are of higher risk for shorter PFS and OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantLutetiumRadiopharmaceuticalsRadioisotopesHumansMaleAgedAged, 80 and overTreatment OutcomeFrail ElderlyCardiovascular DiseasesComorbidityProgression-Free SurvivalProstate-Specific Antigen

Stichwörter der Autor:innen

Lu-177OSPFSSurvivalmCRPC

Substanzen

LutetiumRadiopharmaceuticalsRadioisotopesLutetium-177PluvictoProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
  • Department of Nuclear Medicine, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
  • Urologische Klinik München Planegg, Planegg, Germany.
  • Department of Urology and Urosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Zitieren

APA

Wenzel, M., Siech, C., Garcia, C. C., Humke, C., Groener, D., Kriegmair, M., Graefen, M., Maurer, T., Salomon, G., Banek, S., Chun, F. K. H., & Mandel, P. (2025). Cancer-control outcomes with [ 177 Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patients. Theranostics, 15(7), 2672-2679. https://doi.org/10.7150/thno.108963

Vancouver

Wenzel M, Siech C, Garcia CC, Humke C, Groener D, Kriegmair M, et al. Cancer-control outcomes with [ 177 Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patients. Theranostics. 2025;15(7):2672-2679. doi:10.7150/thno.108963

BibTeX
@article{Wenzel2025,
  author = {Wenzel, Mike and Siech, Carolin and Garcia, Cristina Cano and Humke, Clara and Groener, Daniel and Kriegmair, Maximilian and Graefen, Markus and Maurer, Tobias and Salomon, Georg and Banek, Severine and Chun, Felix K H and Mandel, Philipp},
  title = {Cancer-control outcomes with [ 177 Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patients},
  journal = {Theranostics},
  year = {2025},
  volume = {15},
  number = {7},
  pages = {2672--2679},
  doi = {10.7150/thno.108963}
}
Kostenlos starten →